Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Ordinary Shares, nominal value EUR0.12 per share
-
Shares outstanding
-
113,609,919
-
Total 13F shares
-
98,611,632
-
Share change
-
+21,446,730
-
Total reported value
-
$2,534,320,573
-
Put/Call ratio
-
160%
-
Price per share
-
$25.70
-
Number of holders
-
130
-
Value change
-
+$569,548,998
-
Number of buys
-
82
-
Number of sells
-
47
Institutional Holders of NewAmsterdam Pharma Co N.V. - Ordinary Shares, nominal value EUR0.12 per share (NAMS) as of Q4 2024
As of 31 Dec 2024,
NewAmsterdam Pharma Co N.V. - Ordinary Shares, nominal value EUR0.12 per share (NAMS) was held by
130 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
98,611,632 shares.
The largest 10 holders included
Frazier Life Sciences Management, L.P., Bain Capital Life Sciences Investors, LLC, FCPM III SERVICES B.V., RA CAPITAL MANAGEMENT, L.P., VIKING GLOBAL INVESTORS LP, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), JENNISON ASSOCIATES LLC, Cormorant Asset Management, LP, Medicxi Ventures Management (Jersey) Ltd, and Woodline Partners LP.
This page lists
130
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.